GABRA2 and Dravet syndrome: Future studies assessing efficacy of treatment with AZD7325 or other GABRA2-selective PAMs on spontaneous seizures and survival would provide further support for targeting α2-containing GABAA receptors for the treatment of Dravet syndrome and, potentially, other DEEs that share reduced GABAergic signaling as a common pathogenic mechanism.